Technology plattform

Under the strategic goal of "building a TOP RANKING BIOTECH company", Shenlian Biomedical has always led the way with innovation craftsmanship, and service. After years of research and development, the company has established a"8+X" technology platform,including :Virus-Like Particle Sci-Tech Platform, Synthetic Peptide Sci-Tech Platformand mRNA Vaccine Sci-Tech Platform.
  • Q
    Anti-body Discovery Sci-Tech Platform
    Protein Expression Platform
    Antibody Discovery Platform
    Recombinant Antibody Expression Platform
    Antibody Engineering Platform
  • Q
    Biologics Delivery Sci-Tech Platform
    Match delivery systems based on material characteristics and application requirements
    Reservoir + sustained release, high-loading and long-lasting effect, reducing administration frequency
    Delivery routes include: intramuscular injection, subcutaneous injection, and oral immunization
  • Q
    In vitro diagnostic Technique Platform
    Mammalian Cell Expression
    Post-translation modification of antigens
    Mature monoclonal cell line construction technology
    Stable cell culture process: make rapid scale-up possible

    Bacterial Expression
    Clear genetic background
    Low biosafety risk
    Easy to achieve industrial-scale
    Convenient process and mature system
  • Q
    Novel inactivated vaccine Sci-Tech Platform
    Support from R&D technology platform
    Support from animal experiment platform
    Advanced production line
  • Q
    mRNA vaccine Sci-Tech Platform
    Leading technologies in virus amplification, antigen purification, antigen determination, and antigen preservation
    Double-strain Reverse Genetic Technology
    Double Efficient Suspension Culture Technology
    Double Membrane Integrated Purification Technology
    Bidirectional Antigen Protection Technology
    Double 146S Measurement Technology
  • Q
    Synthetic Peptide Sci-Tech Platform
    Circular RNA technology, known as mRNA technology Version 2.0, offers superior advantages in production, delivery, and treatment
    Safety —— mRNA vaccines do not need to enter the nucleus, and there is no risk of integration into the genome
    Efficacy —— activate humoral immunity and cellular immunity and stimulate strong immune response
    Rapid industrialization —— Short development cycle, low cost, rapid scale-up, and on-demand manufacturing
  • Q
    Virus-Like Particle Sci-Tech Platform
    For the first time in the world, synthetic peptide technology was applied to prophylactic biological product
    Design and construction of ultra-long chain synthetic polypeptide
    “Difficult Peptide” preparation process developed
    Coupling and modification technology of antigen peptides and proteins
    High purity and high yield with industrial-scale polypeptide preparation and purification technology
  • Q
    Protein expression Sci-Tech Platform
    Antigen sequence design method based on big data
    Efficient construction technology of protein expression
    Nanovaccine technology
    Click chemistry enables modular production
    Universal technology allows rapid preparation
    High stability and high efficiency
    Biomimetics affinity chromatography
    Intelligent molecular staple technology
    •
    MSG